Redeye initiates coverage of Corline, traditionally seen as a medtech that sells coated stents but whose real value lies in applying its proprietary heparin technology to regenerative medicine. This underappreciated case hinges on its potential to lift mediocre transplant success rates at a time when US authorities are pushing to replace dialysis. Our stance is clearly positive.